CRDF News and Press, Cardiff Oncology Inc. From 09/08/21

Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival PR Newswire SAN DIEGO , Sept. 8, 2021 /PRNewswire/ -- 8 of 19 (42%) patie...

Cardiff Oncology to Present at Upcoming Investor Conferences in September PR Newswire SAN DIEGO , Sept. 7, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021 PR Newswire SAN DIEGO , Aug. 25, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, devel...

Cardiff Oncology (NASDAQ:CRDF): Q2 GAAP EPS of -$0.17 misses by $0.02. Revenue of $0.07M (+75.0% Y/Y) misses by $0.08M. As of June 30, 2021, Cardiff Oncology had approximately $140 million in cash, cash equivalents and short-term investments. Press Release For further details see: Cardi...

Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates - Lead clinical program of onvansertib in KRAS-mutated metastatic colorectal cancer continues to generate data showing robust response to treatment and progression-free survival - First patien...

Drug-resistant superbugs have threatened human health for decades. The situation is getting worse because of the shortage of new antibiotics. But what if we changed the way we aim to treat them, and trained our cells to kill these invaders instead of relying on antibiotics to do the dirty work...

Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer - Dr. Ruffner is a US-trained hematologist/oncologist with over 25 years of clinical care, oncology biotechnology and pharmaceutical...

Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021 PR Newswire SAN DIEGO , July 6, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. ( Nasdaq: CRDF ) , a clinical-stage biotechnology company developing onv...

Cardiff Oncology (CRDF) was added to the Russell 2000, Russell 3000 and the Russell Microcap indexes as part of the 2021 Russell indexes annual reconstitution, effective June 28 after the U.S. market opens. The company said membership in the U.S. all-cap Russell 3000 Index...